# University of Illinois Chicago: Phase 1 study started recruiting, 17 planned (Plasmablastic Lymphoma, HIV)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | University of Illinois Chicago |
| Sponsor type | Academic and hospital |
| Study | HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV |
| NCT ID | NCT07647432 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Plasmablastic Lymphoma; HIV; Consolidation |
| Intervention types | drug |
| Target enrollment | 17 |
| Site countries | United States |
| Posted | 2026-06-15 |
| Planned start | 2026-10-21 |
| Event | Started recruiting |
| Event date | 2026-10-21 |
| Last update posted | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07647432). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.